| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TYRA | Common Stock | Other | -1,000,000 | -12% | 7,477,275 | 18 Oct 2024 | See footnotes | F1, F2, F3 | ||
| holding | TYRA | Common Stock | 1,496,613 | 18 Oct 2024 | See footnotes | F3, F4 | |||||
| holding | TYRA | Common Stock | 442,721 | 18 Oct 2024 | See footnotes | F3, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TYRA | Pre-Funded Warrants (Right to Buy) | Other | +2,358,457 | 1,000,000 | 18 Oct 2024 | Common Stock | 1,000,000 | $0.001000 | See footnotes | F1, F2, F3, F6 |
| Id | Content |
|---|---|
| F1 | On October 18, 2024, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 1,000,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 1,000,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Exchange Warrant"). |
| F2 | These securities are held directly by the Fund. |
| F3 | RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| F4 | These securities are held directly by the Nexus Fund. |
| F5 | These securities are held directly by the Account. |
| F6 | The Exchange Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Exchange Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. |
Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.